John F. Dee

John F. Dee "has been a director of Verenium since May 2008. He is currently Chairman of the Board of Neurophage, Inc., a pioneering neuroscience company focused on neurodegenerative disorders. He also serves as Chairman of the Board of Bioprocessors, Inc., a leading innovator focused on advancements in bioprocessing for the Life Sciences industry. Previously, he served as President and Chief Executive Officer of Hypnion, Inc. from its founding in 200 until its sale to Eli Lilly in 2007 for $315 million. Under Mr. Dee’s leadership, Hypnion raised approximately $70 million in venture capital, built a world-class scientific team and technology platform, advanced 5 drugs into clinical trials, and positioned itself as the leader in sleep discorder research and development. Prior to Hypnion, Mr. Dee spent a significant portion of is professional career with McKinsey & Co., Inc., where he conducted performance-improvement and strategic growth initiatives for several major energy and pharmaceutical companies. After leaving McKinsey in 1997, he conducted “turnarounds” of biotechnology companies as an acting Chief Executive Officer, including a successful restructuring of Genta, Inc. In non-profit pursuits, Mr. Dee led a group of Bay Area economists and business leaders in a diagnostic and public policy review of the San Francisco Bay Area’s economic performance. He also advised the Pacific Presidio Center, a non-profit environmental group, on the potential redesign of the Presidio army base into a world environment center. Mr. Dee holds an M.S. in Engineering from Stanford University and an M.B.A. from Harvard University."